M Maccario1, R Giordano2, V Gasco1, J Giannelli1, L Campioni1, E Arvat3, E Ghigo1, S Grottoli1. 1. Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy. 2. Division of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences and Department of Clinical and Biological Sciences, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy. roberta.giordano@unito.it. 3. Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy.
Abstract
PURPOSE: Patients with secondary adrenal insufficiency (SAI) have an increased morbidity and an impaired health-related quality of life (HRQoL), which seems to primarily depend on the sub-optimal replacement of hypoadrenalism with standard glucocorticoid (GC) therapy, and on the inadequate correction of other associated pituitary deficiencies. A dual-release hydrocortisone (DR-HC) formulation has shown to exert positive effects on morbidity and HRQoL, mainly in patients with primary adrenal insufficiency. We assessed the variations of anthropometric and metabolic parameters and HRQoL in patients with SAI after switching from cortisone acetate (CA) or hydrocortisone (HC) to DR-HC. METHODS: Twenty-one patients (17 M, 4 F) treated with CA (n = 16; 25 mg/day twice a day) or HC (n = 5; 20 mg/day three times a day), were evaluated for waist circumference, BMI, fasting glucose, HbA1c, insulin, HOMA-IR index, serum lipids, electrolytes, blood pressure and HRQoL at baseline, at 3, 6 and 12 months after switching from CA/HC to DR-HC. RESULTS: The study showed a significant reduction of waist circumference and BMI (p = 0.04, for both), after 3 and 6months of DR-HC treatment, respectively. No significant changes were observed for fasting glucose, insulin, HOMA-IR index, HbA1c, total cholesterol, triglycerides, LDL cholesterol, electrolytes, and blood pressure. However, HDL cholesterol significantly decreased (p = 0.003). An improvement of AddiQoL total score was observed during DR-HC treatment (p = 0.01), mainly for the category "emotions". No predictors resulted for these changes. CONCLUSION: DR-HC treatment provides some benefits in patients with SAI, reducing central adiposity and improving HRQoL; however, worsening of HDL cholesterol is observed during treatment with DR-HC.
PURPOSE: Patients with secondary adrenal insufficiency (SAI) have an increased morbidity and an impaired health-related quality of life (HRQoL), which seems to primarily depend on the sub-optimal replacement of hypoadrenalism with standard glucocorticoid (GC) therapy, and on the inadequate correction of other associated pituitary deficiencies. A dual-release hydrocortisone (DR-HC) formulation has shown to exert positive effects on morbidity and HRQoL, mainly in patients with primary adrenal insufficiency. We assessed the variations of anthropometric and metabolic parameters and HRQoL in patients with SAI after switching from cortisone acetate (CA) or hydrocortisone (HC) to DR-HC. METHODS: Twenty-one patients (17 M, 4 F) treated with CA (n = 16; 25 mg/day twice a day) or HC (n = 5; 20 mg/day three times a day), were evaluated for waist circumference, BMI, fasting glucose, HbA1c, insulin, HOMA-IR index, serum lipids, electrolytes, blood pressure and HRQoL at baseline, at 3, 6 and 12 months after switching from CA/HC to DR-HC. RESULTS: The study showed a significant reduction of waist circumference and BMI (p = 0.04, for both), after 3 and 6months of DR-HC treatment, respectively. No significant changes were observed for fasting glucose, insulin, HOMA-IR index, HbA1c, total cholesterol, triglycerides, LDL cholesterol, electrolytes, and blood pressure. However, HDL cholesterol significantly decreased (p = 0.003). An improvement of AddiQoL total score was observed during DR-HC treatment (p = 0.01), mainly for the category "emotions". No predictors resulted for these changes. CONCLUSION: DR-HC treatment provides some benefits in patients with SAI, reducing central adiposity and improving HRQoL; however, worsening of HDL cholesterol is observed during treatment with DR-HC.
Authors: Helena Filipsson; John P Monson; Maria Koltowska-Häggström; Anders Mattsson; Gudmundur Johannsson Journal: J Clin Endocrinol Metab Date: 2006-08-08 Impact factor: 5.958
Authors: Maria Fleseriu; Ibrahim A Hashim; Niki Karavitaki; Shlomo Melmed; M Hassan Murad; Roberto Salvatori; Mary H Samuels Journal: J Clin Endocrinol Metab Date: 2016-10-13 Impact factor: 5.958
Authors: G Johannsson; A G Nilsson; R Bergthorsdottir; P Burman; P Dahlqvist; B Ekman; B E Engström; T Olsson; O Ragnarsson; M Ryberg; J Wahlberg; B M K Biller; J P Monson; P M Stewart; H Lennernäs; S Skrtic Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Casper Hammarstrand; Oskar Ragnarsson; Tobias Hallén; Eva Andersson; Thomas Skoglund; Anna G Nilsson; Gudmundur Johannsson; Daniel S Olsson Journal: Eur J Endocrinol Date: 2017-06-08 Impact factor: 6.664
Authors: A G Nilsson; C Marelli; D Fitts; R Bergthorsdottir; P Burman; P Dahlqvist; B Ekman; B Edén Engström; T Olsson; O Ragnarsson; M Ryberg; J Wahlberg; H Lennernäs; S Skrtic; G Johannsson Journal: Eur J Endocrinol Date: 2014-06-18 Impact factor: 6.664